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Background: The enhancer of zeste homolog 2 (EZH2) was found to be overexpressed and associated with tumor
metastasis in esophageal squamous cell carcinoma (ESCC). On the other hand, it was reported that miR-26a, miR-98,
miR-101, miR-124, miR-138 and miR-214 could inhibit the expression of EZH2 in some tumors. However, the role of
miRNAs in the regulation of EZH2 expression in human ESCC has not been documented. The aim of this study
was to determine the role of these miRNAs in the regulation of tumor metastasis via EZH2 overexpression in
human ESCC.
Methods and results: The expression of these miRNAs and EZH2 mRNA were examined by qPCR and the
expression of EZH2 protein was detected by western blot. The role of these miRNAs in migration and invasion was
studied in ESCC cell line (Eca109) transfected with miRNA mimics or cotransfected with miRNA mimics and
pcDNA-EZH2 plasmid (without the 3’-UTR of EZH2). Through clinical investigation, we found that miR-98 and
miR-214 expression was significantly lower in ESCC tissues than in matched normal tissues, and the expression
level of miR-98 and miR-214 was inversely correlated to EZH2 protein expression and the clinical features such as
pathological grade, tumor stage and lymph node metastasis in ESCC. In Eca109 cells, overexpression of miR-98
and miR-214 significantly inhibited the migration and invasion of ESCC cells, which was reversed by transfection
of EZH2.
Conclusions: These findings suggest that decreased expression of miR-98 and miR-214 might promote metastasis
of human ESCC by inducing accumulation of EZH2 protein.
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Esophageal squamous cell carcinoma (ESCC) is the
second most common cancer in China [1]. The recur-
rence rate of ESCC is extremely high after surgical
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reproduction in any medium, provided the orMetastasis is a strong independent prognostic factor
for ESCC [4,5]. Therefore, any insight into the
mechanisms of ESCC metastasis may provide import-
ant clues for the development of clinical diagnostic
methods and effective therapeutics [6].
The enhancer of zeste homolog 2 (EZH2, also
called histone lysine methyltransferase) is located at
chromosome 7q35 and encodes a member of the
Polycomb group proteins [7], which regulate gene
expression via epigenetic modification of chromatin
structure including inducing histone acetylation and
methylation [7,8]. Previous studies showed thatd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Figure 1 EZH2 protein but not mRNA expression is increased in
ESCC specimens as compared to matched normal tissues. (A, B)
The expression of EZH2 mRNA and protein in the ESCC specimens
and the matched normal tissues was detected by qRT-PCR and
western blot and normalized to that of GAPDH and β-actin,
respectively. Results showed that the expression of EZH2 mRNA (C)
was comparable between tumor tissue and matched normal tissue,
while the expression of EZH2 protein (D) was significantly increased
in tumor tissue compared with the matched normal tissue. Data are
presented as individual samples (n = 40) with the line indicating the
mean level; **, P< 0.01 by paired t test.
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[9,10]. Moreover, increased EZH2 expression could
significantly promote tumor cell migration and inva-
sion, and is strongly associated with tumor metasta-
sis and poor clinical prognosis in a variety of human
tumors such as breast, prostate, endometrial, gastric,
colon, hepatocellular, bladder and oral cancers [11-
18]. In the case of human ESCC, He et al. [19] and
Tzao et al. [20] independently reported that overex-
pression of EZH2 is associated with tumor metasta-
sis and poor prognosis of the patients. However, the
mechanism underlying EZH2 overexpression in
ESCC remains unclear.
In recent years, accumulating data indicate that ex-
pression of EZH2 is regulated at the posttranscrip-
tional level by a number of microRNAs (miRNAs). It
was reported that miR-26a, miR-98, miR-101, miR-
124, miR-138 and miR214 inhibit the expression of
EZH2 in nasopharyngeal carcinoma, nasopharyngeal
carcinoma, glioblastoma, hepatocellular carcinoma,
head and neck squamous cell carcinoma, and neuro-
blastoma, respectively [21-26]. However, the role of
miRNAs in the regulation of EZH2 expression in
human ESCC has not been documented. Considering
that the expression and function of miRNAs may
vary in different types of tumors, here we set out to
investigate whether these miRNAs (miR-26a, miR-98,
miR-101, miR-124, miR-138 and miR214) regulate
tumor metastasis via altering EZH2 expression in
human ESCC. Through clinical investigation and cel-
lular experiments using ESCC cell line, we demon-
strate that decreased expression of miR-98 and miR-
214 induce accumulation of EZH2 protein and might
thereby promote the metastasis of human ESCC.
Results
EZH2 expression is up-regulated at the
post-transcriptional level in ESCC specimens
In the present study, we examined EZH2 mRNA and
protein expression in ESCC tissues and matched
normal esophageal tissues by qRT-PCR and western
blot analysis. EZH2 mRNA appeared to be higher in
tumor than in the normal tissue in 60% (24/40) of
specimens, but overall the difference in EZH2
mRNA expression between ESCC tissues and the
matched normal tissues was not statistically signifi-
cant (Figure 1A). On the other hand, the expression
level of EZH2 protein was upregulated in tumor in
92.5% (37/40) of specimens with a total average of 2.6
fold increase than in the matched normal tissues
(Figure 1B, Additional file 1: Figure S1). These data
suggest that EZH2 expression is up-regulated at the
posttranscriptional level in human ESCC.MiR-98, miR-101 and miR214 expression is
down-regulated in ESCC specimens
MiR-26a, miR-98, miR-101, miR-124,miR-138 and miR-214
were reported to be decreased in some human tumors and
posttranscriptionally regulate the expression of EZH2
[21-26]. In the present study, we first examined the expres-
sion levels of MiR-26a, miR-98, miR-101, miR-124, miR-
138 and miR214 in clinical samples of ESCC and matched
normal tissues using qPCR. Expression of miR-98 and miR-
101 was found to be downregulated in tumor tissues com-
pared with the matched normal tissues in 67.5% (27/40) of
samples. In 77.5% (31/40) of samples, miR-214 was found to
be downregulated. In 42.5% (17/40) of samples, all the three
miRNAs were downregulated in tumor versus normal tis-
sues. Figure 2A-C shows the mean expression levels of
miR-98, miR-101 and miR-214, which were significantly
lower in tumor tissues than in matched normal tissues. On
the other hand, expression of miR-138 was significantly
higher in tumor tissues than in matched normal tissues
(Figure 2D) and the expression levels of miR-26a and miR-
124 were not significantly different between tumor and
matched normal tissues (Figure 2E and F).
We further investigated the relationship of the expres-
sion level of miRNAs (miR-98, miR-101 and miR214)
with EZH2 expression. It was found that 75% (30/40),
62.5% (25/40), and 85% (34/40) of samples showed down-
regulation of miRNAs (i.e.. miR-98, miR-101 and miR214)
with upregulation of EZH2 protein in tumor versus
normal tissues, respectively. These results suggest that
downregulation of these miRNAs might contribute to
the accumulation of EZH2 protein in tumors. Moreover,
the expression of miR-98 (or miR-214) was inversely cor-
related with EZH2 protein but not mRNA expression in
tumor tissues (Figure 3A-D). On the other hand, there
Figure 2 MiR-98, miR-101 and miR-214 expression is decreased in ESCC specimens as compared to matched normal tissues. The
expression of miRNAs in the ESCC specimens and the matched normal tissues was detected by qRT-PCR and normalized to that of U6. Results
showed that the expression of miR-98 (A), miR-101 (B) and miR-214 (C) were significantly decreased in tumor tissue compared with the matched
normal tissue; while that of miR-138 (D) was significantly increased in tumors tissue, and there was no significantly difference in the expression of
miR-26a (E) and miR-124 (F) between the two groups. Data are presented as individual samples (n = 40) with the line indicating the mean level;
**, P< 0.01 by paired t test.
Figure 3 MiR-98 and miR-214 expression is inversely correlated with that of EZH2 protein. Dot plots represent log10EZH2 protein (mRNA)
relative expression level against log10miRNA relative expression level. The lines represent approximated curves. The correlation coefficient (r) and
the P value indicate the statistical significance of the negative correlation between the x and y variables. Results showed that the expression of
miR-98 was inversely correlated with EZH2 protein (A) but not mRNA expression (B) in tumor cells. Similarly, the expression of miR-214 was
inversely correlated with EZH2 protein (C) but not mRNA expression (D). There was no significant association between the expression of miR-101
and EZH2 protein (E) and mRNA (F).
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expression of miR-101 and EZH2 mRNA and protein
(Figure 3E-F). These data suggest that miR-98 and miR-214
may play an important role in regulating the expression of
EZH2 protein in human ESCC.
MiR-98, miR-101 and miR214 are correlated with
pathological grade, tumor stage and lymph node
metastasis
We further analyzed the relationship of miR-98, miR-101
and miR214 expression with the clinical features including
age, gender, pathological grade, tumor location, tumor stage
and lymph node metastasis in ESCC. For each miRNA,
patients were divided into two groups, high expression
(meaning higher than the mean level) and low expression
(meaning lower than the mean level). It was found that the
expression of miR-98 (or miR-214) was significantly corre-
lated with pathological grade, tumor stage and lymph node
metastasis (Table 1). MiR-101 expression was also signifi-
cantly correlated with tumor stage and lymph node metas-
tasis (Table 1). These results suggest that the miR-98, miR-
101 and miR214 might be involved in metastasis of ESCC.
MiR-98, miR-101 and miR-214 posttranscriptionally
down-regulates EZH2 expression in ESCC cell line
To determine whether the 3'-UTR of EZH2 mRNA is a
functional target of miR-98, miR-101 and miR-214 in ESCCTable 1 Relationship between the expression of miRNAs (miR
Clinical features MiR-98
High Low P Hi
Total 20 20 1
Age (year)
<60 7 9 0.519
≥60 13 11
Gender
Male 16 12 0.168
Female 4 8
Pathological grading




Upper1/3-middle1/3 15 12 0.311
Lower1/3 5 8
Tumor stage
T1/T2 12 3 0.003
T3/T4 8 17
Lymph node metastasis
Negative 13 4 0.004
Positive 7 16cells, we measured the luciferase activity in cells cotrans-
fected with these miRNAs (or control miRNA) and Luc-
EZH2 plasmid (or Luc-EZH2-mut plasmid) in ESCC cell
line (Eca109). qPCR analysis confirmed that Eca109 cells
transfected with miRNA mimics (i.e miR-98, miR-101 or
miR-214) exhibited significantly higher mature miRNA
level than those treated with controls 48 hr posttransfection
(Additional file 2: Figure S2). As shown in Figure 4A-C,
cells cotransfected with miRNAs (ie, miR-98, miR-101 or
miR-214) and Luc-EZH2 plasmid showed a significant de-
crease of reporter activity in comparison with those
cotransfected with control microRNA and Luc-EZH2 plas-
mid. However, the reporter activity were comparable be-
tween cells cotransfected with miRNAs (miR-98, miR-101
ormiR-214) and Luc-EZH2-mut plasmid and cells cotrans-
fected with control microRNA and Luc-EZH2-mut plas-
mid (Figure 4A-C). We further detected the expression of
EZH2 protein and mRNA by western blot and qRT-PCR
in Eca109 cells transfected with miRNAs (miR-98, miR-101
or miR-214). Expression of EZH2 protein was found to be
significantly decreased in cells transfected with miRNAs
(miR-98. miR-101 or miR-214) as compared to cells treated
with control microRNA (Figure 4D). However, EZH2
mRNA expression was not significantly different between
the 2 groups (Figure 4E). These results indicate that the
3'-UTR of EZH2 mRNA is a functional target of miR-98,
miR-101 and miR-214 in ESCC cells.-98, miR-101 and miR-214) and clinical features
MiR-101 MiR-214
gh Low P High Low P
3 27 12 28
7 9 0.215 4 12 0.573
6 18 8 16
7 21 0.122 8 20 0.763
6 6 4 8
7 6 0.135 8 5 0.010
3 10 2 11
3 11 2 12
8 19 0.576 9 18 0.507
5 8 3 10
9 6 0.004 8 7 0.013
4 21 4 21
9 8 0.018 8 9 0.043
4 19 4 19
Figure 4 MiR-98, miR-101 and miR-214 posttranscriptionally down-regulates EZH2 expression in ESCC cell line. (A-C)1 × 106 Eca109 cells
were cotransfected with 50 pmol of miRNAs (or control miRNA) and 1 μg of Luc-EZH2 (or matched Luc-EZH2-mut) plasmid, respectively.
Luciferase reporter assay were performed at 48 hr posttransfection. Results showed that cells transfected with miR-98 + Luc-EZH2 (A), miR-101
Luc-EZH2 (B), miR-214 Luc-EZH2 (C) exhibited a significant decrease of reporter activity in comparison with those cotransfected with control
microRNA+ Luc-EZH2 plasmid. However, the reporter activity of cells cotransfected with miRNAs and Luc-EZH2-mut plasmid showed no
significant difference with that of cells cotransfected with control miRNA and Luc-EZH2-mut plasmid. (D, E) 1 × 106 Eca109 cells were transfected
with 50 pmol of miRNAs (or control microRNA), respectively. The expression level of EZH2 mRNA and protein was detected by qPT-PCR an
Western Blot at 48 hr posttransfection and normalized to that of GAPDH and β-actin, respectively. Results showed that the level of EZH2 protein
(D) was significantly decreased in cells transfected with miRNAs (including miR-98, miR-101 and miR-214) as compared to the cells transfected
with control microRNA, while the expression level of EZH2 mRNA (E) exhibited no significantly difference between cells transfected with miRNAs
and those transfected with control microRNA. Data represent mean± SEM from 4 independent experiments; *, P< 0.05, **, P< 0.01 by t test.
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invasion of ESCC cell line
To investigate the role of miR-98, miR-101 and miR-214
in ESCC metastasis, we detected the migrant and inva-
sive capacity of Eca109 cells transfected with miRNA
mimics or control miRNA. Through transwell assay, we
found that the percentage of cells travelled through the
micropore membrane was significantly decreased in cells
transfected with miRNAs (miR-98, miR-101 or miR-214)
as compared to those cells transfected with control
miRNA (Figure 5A). In addition, using matrigel-coated
transwell assay, we found that the percentages of cells
that invaded through the matrigel in miRNAs (miR-98,
miR-101 or miR-214) transfected cells were significantlylower than those in the control groups (Figure 5 B).
These results indicate that miR-98, miR-101 and miR-214
could inhibit the migration and invasion of ESCC
cells.
Overexpression of EZH2 reverses the inhibition of
migration and invasion of ESCC cells by miR-98 and
miR-214
To investigate the functional connection between miRNAs
(miR-98, miR-101 and miR-214) and EZH2 in the
regulation of ESCC metastasis, we further evaluated
the migration and invasion capacity of cells cotransfected
with these miRNAs and pcDNA-EZH2 (or empty pcDNA)
plasmid. Notably, the pcDNA-EZH2 plasmid was designed
Figure 5 MiR-98, miR-101 and miR-214 inhibits the migration and invasion of ESCC cells. Eca109 cells were transfected with 50 pmol of
miRNAs (or control microRNA). Migration and invasion of cells were analyzed at 72 hr post-transfection. (A) Transwell assay. Photographs
represented the cells travelled through the micropore membrane and histogram showed the percentage of migrant cells. (B) Matrigel-coated
transwell assay. Photographs represented the cells invaded through the matrigel and histogram showed the percentage of invasive cells.
Bars = 100 μm. Data represent mean± SEM from 4 independent experiments; *, P< 0.05; **, P< 0.01 by t test.
Figure 6 Re-expressing EZH2 significantly attenuates the effect of miR-98 and miR-214 on the inhibition of ESCC cell migration and
invasion. Eca109 cells were co-transfected with 50 pmol of miRNAs and 1 μg of pcDNA-EZH2 (or empty pcDNA3.1) plasmid. Migration and
invasion of cells were analyzed at 72 hr post-transfection. (A) Transwell assay. Photographs represented the cells travelled through the micropore
membrane and histogram showed the percentage of migrant cells. (B) Matrigel-coated transwell assay. Photographs represented the cells
invaded through the matrigel and histogram showed the percentage of invasive cells. Bars = 100 μm. Data represent mean± SEM from
4 independent experiments; *, P< 0.05; **, P< 0.01 by t test.
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3'-UTR. As shown in Additional file 3: Figure S3, EZH2
protein expression was significantly higher in pcDNA-
EZH2 transfected cells than in pcDNA transfected cells.
Compared with cells cotransfected with miR-98 (or
miR-214) and empty cDNA plasmid, a significantly higher
percentage of cells cotransfected with miR-98 (or miR-214)
and pcDNA-EZH2 plasmid travelled through the micro-
pore or invaded through the matrigel (Figure 6A and B).
However, the percentage of cells that travelled through the
micropore or invaded through the matrigel were com-
parable between cells cotransfected with miR-101 and
pcDNA-EZH2 plasmid and cells cotransfected with miR-
101 and pcDNA plasmid (Figure 6A and B). These results
show that overexpression of EZH2 could reverse the inhibi-
tory effect of miR-98 and miR-214 on cell migration and
invasion.
Discussion
EZH2 has been identified as a transcriptional repressor
and is implicated in the aggressiveness and metastasis of
many types of human cancers including ESCC [19,20]. In
recent years, it was reported that some miRNAs could
regulate EZH2 expression at the post-transcriptional
level in several types of tumors [21-26]. In the present
study, we show that miR-98 and miR-214 expression in
ESCC tissue are inversely correlated with the clinical fea-
tures such as pathological grade, tumor stage and lymph
node metastasis. In Eca109 cells, overexpressing miR-98
and miR-214 was found to significantly suppress cell
migration and invasion through inhibition of EZH2
expression.
Previous studies showed that the expression of EZH2
is regulated at the transcriptional and posttranscriptional
levels [21-27]. Tang et al. [27] reported that p53 could
inhibit the transcription of EZH2 by binding to the pro-
moter of EZH2 in prostate cancer. On the other hand,
mounting evidence indicate that some miRNAs could ef-
fectively repress the expression of EZH2 in tumors such
as breast, prostate, endometrial, gastric, colon, hepato-
cellular, bladder and oral cancers [21-26]. In the present
study, we detected EZH2 protein and mRNA expression
in ESCC tumor tissues and matched normal tissues by
western blot and qRT-PCR. It was found that the expres-
sion level of EZH2 protein was significantly higher in
tumor tissues than in matched normal tissues, despite
that EZH2 mRNA expression was comparable between
the two groups. These results suggest that EZH2 expres-
sion is upregulated in human ESCC mainly at the post-
transcriptional level.
MiRNAs are evolutionarily conserved small noncoding
RNAs (21–25 nucleotides) that regulate gene expression
through modulation of translation efficiency or degrad-
ation of mRNAs [28,29]. It was reported that miR-26a,miR-98, miR-101, miR-124, miR-138 and miR-214 were
involved in the regulation of EZH2 expression in some
human tumors such as nasopharyngeal carcinoma,
nasopharyngeal carcinoma, glioblastoma, hepatocellular
carcinoma, head and neck squamous cell carcinoma,
and neuroblastoma [21-26]. In the present study, we
compared the expression level of these miRNAs in
ESCC tissues and matched normal tissues by qPCR.
We found that expression levels of miR-98, miR-101
and miR-214 were significantly lower in tumor than in
normal tissues. On the other hand, miR-138 expression
was significantly higher in tumor than in normal tis-
sues and miR-26a and miR-124 expression was com-
parable between the two types of tissues. Using
luciferase assay and western blot, we further demon-
strated that miR-98, miR-101 and miR-214 could target
the 3’-URT of EZH2 and suppress EZH2 expression in
ESCC cells. Combining these findings, we propose that
miR-98, miR-101 and miR-214 regulate the accumula-
tion of EZH2 protein in ESCC.
MiR-98 belongs to the mature let-7 family of miRNAs
[30] and was initially found to be down-regulated in
leukemia cell lines [31]. Subsequent studies showed that
the expression of miR-98 were also significantly de-
creased in solid tumors such as nasopharyngeal carcin-
oma, head and neck squamous cell carcinoma [22,32].
Therefore, miR-98 is wildly regarded as a tumor sup-
pressor gene. On the other hand, the expression and
function of miR-214 appears to be cell type- and dis-
ease-specific. It was reported that miR-214 was down-
regulated in breast and cervical cancer and acted as a
tumor suppressor gene in these tumors since its overex-
pression inhibits cell proliferation and invasion [26,33].
By contrast, other studies showed that miR-214 was
over-expressed in pancreatic and ovarian cancers and its
overexpression promotes cell survival and chemotherapy
resistance [34,35]. In the present study, we found that
miR-98 and miR-214 expression were both inversely cor-
related with EZH2 protein expression in human ESCC,
and that down-regulation of miR-98 and miR-214 ex-
pression was significantly correlated with pathological
grading, tumor stage and lymph node metastasis. More-
over, overexpression of miR-98 or miR-214 could sig-
nificantly inhibit ESCC cell migration and invasion,
which was reversed by over-expressing EZH2. These
findings suggest that miR-98 and miR-214 may play an
important role in inhibiting the metastasis of ESCCs by
targeting EZH2.
MiR-101 was reported to be down-regulated in human
colon cancer, nasopharyngeal carcinoma, neuroblastoma
and prostate cancer, and could repress the proliferation,
invasion and metastasis of tumor cells [22,23,36,37]. In
the present study, we found that miR-101 expression
was down-regulated in primary ESCC tumor tissues and
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lymph node metastasis. Although in Eca109 cells, over
expression of miR-101 was found to suppress EZH2 ex-
pression, we did not detect significant correlation be-
tween the expression of miR-101 and EZH2 in clinical
samples of ESSC tumor tissues and we found that miR-
101-induced inhibition of Eca109 migration and invasion
was not reversed by overexpressing EZH2. The discrep-
ancies might be attributable to the regulation of EZH2
expression by multiple miRNAs, amongst which miR-
101 only plays a minor role. Further studies are needed
to test whether miR-101 might inhibit ESCC metastasis
via an EZH2-independent signal pathway.
In summary, we have demonstrated that the expres-
sion of miR-98 and miR-214 was significantly lower in
ESCC tissues than in matched normal tissues and that
down-regulation of miR-98 and miR-214 was correlated
with the up-regulated EZH2 protein expression, poor
pathological grade, advanced tumor stage and lymph
node metastasis in ESCC. In Eca109 cells, miR-98 and
miR-214 overexpression significantly inhibited cell mi-
gration and invasion by repressing EZH2 protein ex-
pression. We propose that miR-98 and miR-214 are
tumor suppressor genes in ESCC. It would be interest-
ing to test whether these miRNAs act synergistically to
regulate ESCC cell migration and invasion. Further
experiments in animal models are warranted to estab-
lish the role of these miRNAs and EZH2 in regulating
ESCC metastasis.Material and method
ESCC specimens
A total of forty primary ESCC patients that underwent
esophagectomy were enrolled in this study. Tumor speci-
mens and paired normal esophageal tissue specimens
taken from a site distant from the cancerous lesion were
obtained from the consenting patients, as approved by
the Medical Ethics Committee of Changhai Hospital.
None of the patients received radiotherapy or chemo-
therapy before surgery. Clinical and pathological data in-
cluding age, gender, pathological grading, tumor location,
tumor stage and lymph node metastasis were acquired
from the medical records.Cell culture
Human ESCC cell line Eca109 was purchased from the
Shanghai Institute of Biochemistry and Cell Biology
(Shanghai, China). Cells were maintained in RPMI1640
(Invitrogen) supplemented with 10% fetal bovine serum
(Invitrogen), 100 U/ml penicillin and 100 μg/ml strepto-
mycin, within a humidified atmosphere containing 5%
CO2 at 37°C.Cell transfection
Cells were cultured to 1 × 106/ well in 6-well cell culture
plate and were then transfected with 50 pmol of miRNA
double-stranded mimics (or control miRNA) using Lipo-
fectamine 2000 (Invitrogen) according to the manufac-
turer’s protocol Transfection efficiency was optimized
using 6-carboxyfluorescein-labeled microRNA at ap-
proximately 80% in Eca109 cells.
The sequences of miR-98 were:
Sense: 50- UGAGGUAGUAAGUUGUAUUGUU −30,
Anti-sense: 50- AACAAUACAACUUACUACCUCA −30,
The sequences of miR-101 were:
Sense: 50- UACAGUACUGUGAUAACUGAA −30,
Anti-sense: 50- UUCAGUUAUCACAGUACUGUA −30,
The sequences of miR-214 were:
Sense: 50- ACAGCAGGCACAGACAGGCAGU −30,
Anti-sense: 50- ACUGCCUGUCUGUGCCUGCUGU−30,
A scrambled microRNA with no homology to any
known human microRNA was used as negative control:
Sense: 50-GUUGAACUGUUAAGAACCACUGG-30,
Anti-sense: 50-CCAGUGGUUCUUAACAGUUCAAC-30,
All microRNA mimics were synthesized by Gene-
phama Biotech (Shanghai, China).
Quantitative reverse transcription polymerase chain
reaction (qRT-PCR)
Total RNA was extracted from 100 mg tissues or
1 × 105 cells using the RNeasy RNA Mini Kit (Qiagen).
First strand cDNA was synthesized using POWER-
SCRIPT reverse transcriptase (Clontech). The following
gene-specific primer pairs were used for quantitative
PCR:
EZH2: Forward, 50- TTACTTGTGGAGCCGCTGAC -30;
Reverse, 50- TCAGATGGTGCCAGCAATAG-30.
GAPDH: Forward, 50- GCTGAGTATGTCGTGGAGTC -30;
Reverse, 50- AGTTGGTGGTGCAGGATGC -30.
PCR was performed using a Fast Start Master SYBR
Green Kit (Roche) on a LightCycler (Roche). The ex-
pression level of target gene mRNA was analyzed using
RealQuant software (Roche) and normalized to that of
GAPDH mRNA.
Cell lysis and western blot
Cellular proteins were prepared using cell lysis buffer
(50 mM Tris–HCl, pH 8.0, 1% NP-40, 2 mM EDTA,
10 mM NaCl, 2 mg/ml aprotinin, 5 mg/ml leupeptin,
2 mg/ml pepstatin, 1 mM DTT, 0.1% SDS and 1 mM
phenylmethylsulfonyl fluoride). Equal amounts of pro-
tein (50 μg) were separated by 10% SDS PAGE and then
transferred to nitrocellulose membranes (NY, USA) by
electroblotting. The membranes were blocked with 5%
BSA in TBST (10 mM Tris–HCl, pH 8.0, 150 mM NaCl,
and 0.05% Tween 20) for 1 hr, and then incubated with
mouse anti-human EZH2 antibody (Santa Cruz)
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horseradish peroxidase-conjugated goat anti-mouse anti-
body (BD) for 1 hr at 37°C. Protein was visualized using
enhanced chemiluminescence reagent (Santa Cruz). The
expression level of EZH2 protein was analyzed using
LabWork 4.0 program (UVP) and normalized to that of
β-actin protein.Luciferase reporter assay
The full-length 30-UTR of EZH2 mRNA was amplified by
PCR (Forward: 50-CTAGTCATCTGCTACCTCCTCC-30;
Reverse: 50-AGCTTACAAGTTCAAGTATTCTTTATTC-
30). Mutant EZH2 30-UTR, which carried a substitution
of four nucleotides (AGGU to UCCA for miR-98, UACU
to AUGA for miR-101, and CAGC to GUCG for miR-
214) within the core binding sites of EZH2 30-UTR, was
obtained using overlapping extension PCR. Normal (or
mutant) EZH2 30-UTR was cloned into the SacI-HindIII
site of the pMIR-REPORT luciferase vector (Biosystems)
and named as Luc-EZH2 (or Luc-EZH2-mut). Then,
1 × 106 cells were cotransfected with 50 pmol of miRNAs
(or control miRNA), 1 μg of Luc-EZH2 (or matched
Luc-EZH2-mut) plasmid, and 1 μg of pMIR-REPORT
β-Gal vector using Lipofectamine 2000. The Lucifer-
ase activity was examined at 48 hr posttransfection
using the luciferase assay kit (Clontech) and normal-
ized to β-galactosidase activity.Transwell assay
Cell migration and invasion were determined using a
transwell (Costar) with a pore size of 0.8 μm. 1 × 103
cells were seeded in serum-free medium in the upper
chamber (normal chamber for migration assay and
matrigel-coated chamber for invasion assay). The lower
chamber was filled with medium containing 10% FBS.
After incubating for 8 hr at 37°C, cells in the upper
chamber were carefully removed with a cotton swab and
the cells that had traversed to reverse face of the mem-
brane were fixed in methanol, stained with Giemsa, and
counted.Statistical analysis
Statistical significance was tested using SPSS15.0 soft-
ware. For comparison of clinical features (except for
pathological grading) between high and low miRNA
expression groups, chi-square test was performed. The
correlation between the expression of miRNA and
pathological grade was analyzed by Cochran-Mantel-
Haenszel Statistics. The correlation between the ex-
pression of miRNA and EZH2 was analyzed using
Pearson’s correlation analysis. Other data are presented
as mean ± SEM, using student t tests for 2-groupcomparison. A P value less than 0.05 is considered as
statistically significant.
Additional files
Additional file 1: Figure S1. The expression level of EZH2 protein in
ESCC and paired normal tissues.
Additional file 2: Figure S2. The expression levels of miRNAs were
significantly increased in Eca109 cells transfected with miRNA mimics.
Additional file 3: Figure S3. The expression levels of EZH2 was
significantly increased in Eca109 cells transfected with pcDNA.EZH2.
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